TrumpRx Generic Expansion

Executive summary

Americans are cautiously hopeful about TrumpRx's expansion to 600 generic drugs — but independent reporting suggests that optimism may be running ahead of reality. Six in ten survey respondents view the move positively, yet Reuters and KFF Health News have both found that prices on the platform are not consistently lower than what patients in the UK or Germany pay, directly contradicting the White House's "cheapest in the world" promise.

The expansion matters because it finally adds generics — the category that fills 9 in 10 U.S. prescriptions — after TrumpRx launched covering only branded drugs. But 600 listings represent less than 2% of FDA-approved generics, the platform operates as a cash-only tool that doesn't count toward insurance deductibles, and three-quarters of respondents already fill prescriptions at local pharmacies. Meanwhile, drug cost burdens are measurably worsening: 67% of Americans who fill prescriptions now call costs a financial burden, up from 64% in 2024, and medication rationing has jumped from 15% to 20% in a single year. The urgency is real. Whether TrumpRx is the answer is a much harder question.

Context

TrumpRx.gov launched in the fall of 2025 with a high-profile Pfizer deal promising average discounts of 50% — but only for cash-paying patients not using insurance, and only for branded drugs. The platform is built around a simple idea: let Americans compare direct-to-consumer cash prices across a handful of pharmacy and drug-discount partners, including Mark Cuban's Cost Plus Drug Company, GoodRx, and Amazon Pharmacy. All three operate outside traditional pharmacy benefit manager (PBM) structures, which the FTC has linked to dramatic markups on specialty generics.

The 600-generic expansion announced in May 2026 represents a meaningful course correction. Generics account for 90% of all U.S. prescriptions filled and saved the healthcare system $430 billion in 2023 alone. Launching TrumpRx without them was a structural gap the administration has now moved to address — at least partially.

This pulse survey captured 78 respondents in May 2026, asking about their sentiment toward the expansion, where they currently get prescriptions, and how drug costs affect their household finances. The sample is not nationally representative, but the distribution patterns closely track national benchmarks on pharmacy usage and cost burden — lending real interpretive weight to the results. Open-ended responses on government-private partnerships and household budget impact provide texture that the multiple-choice questions alone cannot capture.

The backdrop is a worsening affordability crisis. GoodRx Research's 2025 national survey (n=1,278) found that 38% of Americans are worried about affording medications this year, up sharply from 27% in 2024. More than 80% of U.S. adults consider drug prices unreasonable. That context makes TrumpRx a politically and economically consequential initiative — even if its actual pricing impact remains contested.

Findings

Most Americans Are Optimistic — But the Skeptics May Be Right

Sixty-two percent of respondents view the TrumpRx expansion positively: 46.2% called it "very positive — this will help many people," and another 15.4% said it was "good but limited impact." Only 14.1% expressed outright skepticism, while 23.1% took a neutral wait-and-see position.

That headline optimism, however, sits uncomfortably alongside independent reporting. Reuters conducted a direct price comparison and found TrumpRx prices are not lower than what patients in the United Kingdom pay — a country where the government negotiates drug prices nationally. KFF Health News similarly found the platform's scope "remains uncertain" and "certainly less than what the announcement promised." The administration claims the platform's most-favored-nation pricing deals will generate $64.3 billion in federal and state savings over a decade, but the specific terms of manufacturer agreements remain confidential, making independent verification impossible.

The implication: the 23.1% who said "need to see how it works" are probably the most analytically grounded cohort in this survey. And the 14.1% who are outright negative may be better-calibrated than their minority share suggests.

Three-Quarters of Users Are Already Where TrumpRx Sends Them

Seventy-six percent of respondents fill most prescriptions at a local pharmacy. Only 7.7% use online or mail-order channels — the distribution model TrumpRx most closely resembles.

This behavioral baseline creates a subtle but important irony. TrumpRx doesn't actually sell drugs. It's a price-comparison tool that redirects users to local pharmacies for cash-pay pickup — meaning its primary audience overlaps heavily with the people already using those pharmacies. The question isn't whether patients will change where they go, but whether they'll change how they pay. For the majority who currently use insurance at those same pharmacies, TrumpRx offers nothing: cash payments through the platform don't count toward deductibles or out-of-pocket maximums.

Nationally, brick-and-mortar pharmacies account for 90% of all prescription fulfillment. Online pharmacies represent at most 1% of the total market. TrumpRx's design — partnering with both local pharmacy price-comparison and DTC channels — is structurally smarter than a pure online model, but the cash-only constraint still walls off the majority of insured Americans.

Drug Cost Burden Is Rising Fast, and Respondents Feel It

Free-response answers to "how much do high prescription drug costs affect your household budget" clustered around the high end of the scale, with scores of 3 to 5 on a 5-point impact scale. Respondents cited diabetes medication, blood pressure drugs, and general unaffordability as pressure points.

National data confirms this isn't just this sample. GoodRx Research's 2025 survey found 67% of prescription-fillers call costs a burden — up from 64% in 2024. Twenty percent rationed medications due to cost this year, up from 15% last year. Thirteen percent stopped a medication entirely, up from 8%. Nearly half of Americans (46%) took some negative financial or lifestyle action because of drug costs in 2025, up from 37% the year before.

This accelerating burden is the strongest argument for TrumpRx's existence. The demand is unambiguously real. The unresolved question is whether the platform's actual price structure is up to the job.

600 Generics Fills a Gap — But It's Still a Sliver of the Market

The expansion to 600-plus generics is genuinely significant because TrumpRx launched covering only branded drugs — an extraordinary oversight given that generics fill 9 in 10 prescriptions in America. The addition more than triples the platform's initial offering.

But context matters. The FDA has approved more than 35,000 generic drugs. Six hundred listings represent less than 2% of that universe. The expansion also explicitly excludes controlled substances, REMS drugs, and medications not commonly offered through direct-to-consumer channels — categories that include many of the drugs patients most urgently need and least afford.

The partnership with Cost Plus Drug Company provides the most independently validated savings mechanism on the platform. A retrospective analysis of 2021 Medicare Part D data found that applying Cost Plus 90-day pricing could have generated $8.6 billion in savings, with nearly 80% of examined drugs more cost-effective through Cost Plus than through Medicare Part D. The highest savings concentrations were in cardiology, psychiatry, neurology, and transplant surgery — all high chronic disease burden categories.

Free-response themes from respondents on government-private partnerships captured the full tension: hopes for lower out-of-pocket prices on diabetes and other chronic condition drugs, paired with sharp skepticism about whether prices would actually fall, whether corporate partners would profit more than patients would save, and whether PBMs — not addressed by TrumpRx at all — were the real problem all along. The FTC's January 2025 report found the Big 3 PBMs marked up specialty generics by thousands of percent and generated more than $7.3 billion above acquisition costs from 2017–2022. TrumpRx bypasses PBMs entirely — which is structurally promising — but leaves the broader PBM system untouched for the insured majority.

Conclusion

TrumpRx's 600-generic expansion taps into genuine and worsening financial pain — the kind that pushes one in five Americans to ration their medications. The public's cautious optimism reflects that real need. But the platform's actual design — cash-only, excluding insurance, covering less than 2% of available generics, with confidential manufacturer terms — means delivery will be harder than the announcement implies.

Watch three things over the next six to twelve months. First, whether independent price audits show TrumpRx generics consistently undercutting existing GoodRx, Amazon, and retail cash prices — or merely aggregating them. Second, whether HHS moves from its January 2026 OIG guidance toward a permanent regulatory safe harbor for direct-to-consumer pricing, which would structurally expand what TrumpRx can offer. Third, whether Congress advances PBM reform legislation: as long as the middleman markup system operates at full scale for the insured majority, platforms like TrumpRx will remain a useful tool for the margins rather than a solution for the mainstream.

The skeptics in this survey — 14% outright negative, 23% neutral — may ultimately be proven correct. The optimists are not wrong about the problem. The jury is still out on whether this is the fix.